Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $15
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $18 to $15.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers MyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 11.9% to $2.25 during Friday’s after-market session. The market value of their…
Goldman Sachs Maintains Buy on Cytek Biosciences, Lowers Price Target to $14
Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and lowers the price target from $16 to $14.
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Amesite Inc. (NASDAQ: AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users.
Earnings Outlook For Cytek Biosciences
Cytek Biosciences (NASDAQ:CTKB) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement.
Analysts estimate that Cytek Biosciences will report an earnings per share (EPS) of $0.02.
Piper Sandler Maintains Overweight on Cytek Biosciences, Raises Price Target to $16
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and raises the price target from $12 to $16.
Recap: Cytek Biosciences Q2 Earnings
Cytek Biosciences (NASDAQ:CTKB) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:03 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 10, 2022
Companies Reporting Before The Bell
• Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.
Earnings Preview: Cytek Biosciences
Cytek Biosciences (NASDAQ:CTKB) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement.
Where Cytek Biosciences Stands With Analysts
Cytek Biosciences (NASDAQ:CTKB) has observed the following analyst ratings within the last quarter: